



IZOTROPIC
CORPORATION

CSE: **IZO** OTCQB: **IZOZF**



For illustrative purposes only. Not yet approved for sale

The only publicly-traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. IzoView produces high resolution breast images in true 3D with low radiation dose levels, and is ideal for imaging patients with dense breast tissue.

A single 10 second scan acquires approximately 500 images, without painful breast compression or continual technician breast handling, providing a more comfortable patient experience.

PROVEN TECHNOLOGY

Making university academic prototypes commercial-ready by integrating FDA insight, hardware and software upgrades for improved performance and platform applications.

CLINICAL STUDY

The initial clinical study intends to demonstrate the superior performance of diagnostic Breast CT imaging over diagnostic mammography procedures.

\$5B MARKET SIZE

This year breast cancer surpassed lung cancer as the most common form of the disease. IzoView Platform plans to address unmet needs across screening, diagnosis, biopsy, treatment and monitoring.

PRICING & REVENUE

IzoView system will be priced less than half of whole-body MRI. Additional revenue items include maintenance contracts, sterile disposables, software feature upgrades, and additional hardware modules.


TEAM TO EXECUTE

Renowned and globally recognized team of breast imaging scientists, medical device engineers, and a CEO with billion dollar exits on his track record.

CUSTOMER DEMAND

Izotropic is receiving requests from around the world from patients, doctors, hospitals and providers, and is making strategic plans to expedite access to IzoView Breast CT.

WATCH IZOVIEW ON YOUTUBE




Click the image to learn what IzoView Breast CT is, how it works, and why patients, insurance providers and customers want IzoView now!

MARKET CAPITALIZATION & COMPARABLES

As at January 3, 2022

52 WK CSE:	\$0.285 - 0.95
52 WK OTCQB:	\$0.193 - 0.74
SHARES:	51,855,021
WARRANTS:	7,851,094
OPTIONS:	4,325,000
FULLY DILUTED:	64,031,115
MARKET CAP:	\$36.8M
FULLY DILUTED:	\$45.4M
25%	DIRECTOR & ADVISOR OWNERSHIP



CONTACT

IR@izocorp.com
1-833-IZOCORP
izocorp.com



MESSAGE ON WHATSAPP



FOLLOW ON TWITTER



WATCH ON YOUTUBE

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections and expectations of the company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such they may cause future results of the company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the company nor its shareholders, officers and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this document should be deemed to be medical or other advice of any kind. Images are for illustrative purposes only. IzoView is not yet approved for sale.